Loading stock data…
KalVista Pharmaceuticals (KALV)
$27.00
Market Closed
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
KalVista Pharmaceuticals, Inc. in the Healthcare sector is trading at $27.00 with a market capitalization of $1.4B. Wall Street consensus targets $27.00 (3 analysts), implying a +0.0% move over the next 12 months. The stock is currently near its 52-week high of $27.00, remaining 59.0% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q3 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $40.86M↑ | $13.69M↑ | $1.43M | $0 | $0 |
| Gross Profit | $37.77M↑ | $12.46M↑ | $836,000 | — | — |
| Operating Income | -$23.44M↑ | -$46.05M↑ | -$59.01M↓ | -$50.02M↓ | -$42.94M |
| Net Income | -$23.49M↑ | -$49.48M↑ | -$60.10M↓ | -$52.23M↓ | -$48.51M |
Peer Comparison
JNJUNHPFE
Fundamentals
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs. Its lead product candidate is EKTERLY, a fast-acting potent inhibitor of plasma kallikrein for the treatment of a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.44B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
942.86%
Volume
Today's trading volume
4.26M
Recent News
KalVista Pharmaceuticals (KALV) Upgraded to Buy: What Does It Mean for the Stock?
KalVista Pharmaceuticals (KALV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
KalVista's (KALV) Chief Development Officer Sells 33,800 Shares for $905,000
This clinical-stage biotech focused on rare diseases reported a notable insider sale amid a year of strong stock performance.
A Look At KalVista Pharmaceuticals (KALV) Valuation After A Strong Year Of Share Price Gains
KalVista Pharmaceuticals (KALV) has attracted attention after a strong move in recent months, prompting investors to reassess what the current share price implies about its rare disease pipeline and financial profile. See our latest analysis for KalVista Pharmaceuticals. That recent surge in buying interest sits on top of a strong run, with a 30-day share price return of 32.8% and a 1-year total shareholder return of 119.2%. This points to momentum that has built gradually rather than in a...
Chiesi widens rare disease portfolio with $1.9bn KalVista buyout
Chiesi will assume ownership of Ekterly, an on-demand pill approved for hereditary angioedema.
IBT portfolio manager says KalVista deal signals Biotech 2.0 growth
International Biotechnology Trust (LSE:IBT) portfolio manager Ailsa Craig tells Proactive's Stephen Gunnion that M&A activity in biotech is running hot, with the proposed KalVista Pharmaceuticals acquisition by Chiesi Farmaceutici the latest in a string of deals — and 15% of IBT's portfolio has now been acquired year-to-date at an average premium of 50%. Craig explains the structural driver: big pharma is cash-rich but facing hundreds of billions in revenues lost to patent expiries, forcing them to acquire innovation. With biotech firms accounting for 70% of new drug approvals last year, the sector is firmly in the crosshairs. KalVista is held up as a textbook example of what Craig calls "Biotech 2.0" — clinically de-risked companies addressing real unmet needs. Its oral HAE treatment replaced injectable therapies, and Craig puts it simply: when patients feel an attack coming on, they now just take a tablet. IBT recycles proceeds from exits straight back into new opportunities, keeping the portfolio actively positioned to benefit from continued dealflow. For more insights like this, visit Proactive's YouTube channel, like this video, subscribe to the channel, and enable notifications so you never miss future updates. #Biotech #Pharma #MergersAndAcquisitions #BiotechInvesting #HealthcareStocks #KalVista #DrugDevelopment #InvestingInsights #BiotechNews #PharmaIndustry #StockMarket #HealthcareInnovation